#ASCO18: Don’t write off IDO yet, says NewLink

At last year’s ASCO, IDO inhibitors were being hailed as the next big thing in cancer immunotherapy, but a series of trial setbacks took that optimism down a notch. Now, armed with new data on its lead IDO drug indoximod, NewLink Genetics insists there is still hope for the class.